Home Featured Page 22

Featured

Latest

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in...

Joshua White – Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Oakland Psychedelic Conference

Kayse Gehret – The Modern Guide: Microdosing, Facilitation & Community

The VA, Psychedelics, and the Future of Mental Health: A Conversation...

Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability...

Harry Pack – Psychedelic Surealism

Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape...

1...212223...306 Page 22 of 306

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a...

Joshua White – Fireside Project and Lucy, an AI Training Simulator...

Did New Jersey Really Just Legalize Psilocybin?

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in...

Joshua White – Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Psychedelic Science 2025

Oakland Psychedelic Conference

Kayse Gehret – The Modern Guide: Microdosing, Facilitation & Community

LP Giobi – Livestream

The VA, Psychedelics, and the Future of Mental Health: A Conversation...

Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability...

Harry Pack – Psychedelic Surealism

Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape...

EDITOR PICKS

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a...

Joshua White – Fireside Project and Lucy, an AI Training Simulator...

Did New Jersey Really Just Legalize Psilocybin?

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY